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ABSTRACT
Background Chronic fatigue is a feature in a subset of 
women successfully treated for breast cancer but is not 
well characterised. This study examines differences in 
objective cognitive function, activity levels and sleep in 
disease-free women who do and do not meet criteria for 
cancer-related fatigue syndrome (CRFS).
Methods Women between 3 months and 2 years 
after completion of any primary therapy were recruited 
from a cancer centre follow-up clinic. On the basis 
of a diagnostic semi-structured interview they were 
classifi ed as being CRFS cases or non-fatigued controls. 
Participants underwent objective cognitive testing 
using a computerised battery, wore an activity monitor 
for 1 week and completed quality of life and fatigue 
questionnaires.
Results 114 women were recruited (69 controls and 
45 CRFS cases). There were signifi cant differences 
between groups on fatigue, mood, sleep and quality of 
life scores, and in objective cognitive testing (tests of 
sustained attention, reaction time and verbal memory 
all p<0.03). There was an overall difference in daytime 
activity (p=0.03) from actigraphy recordings. There 
were no differences on objective measures of sleep or in 
routine laboratory measures.
Conclusions Our preliminary results suggest that 
disease-free women with CRFS after successful breast 
cancer treatment have signifi cantly lower subjective 
quality of life and mood. Additionally, objective cognitive 
impairment in certain domains may play an important 
role in the subjective manifestation of these symptoms. 
There is also objective evidence on actigraphy of 
differing levels of activity. The subjective sleep 
disturbance and higher prevalence of insomnia do not 
correlate with objective measures.
INTRODUCTION
Two thirds of women diagnosed with breast can-
cer today are likely to survive for at least 20 years.1 
As a result more women are living with the longer-
term side-effects of treatment. These can include 
neurocognitive changes,2 3 sleep disturbance,4 
quality of life impairment and persistent fatigue.5 
Of the many symptoms associated with cancer 
and its treatment, fatigue is probably the most 
under-recognised and poorly managed.6
We have previously undertaken a systematic 
review of the literature regarding the prevalence 
of fatigue in breast cancer survivors (BCS).7 Many 
of the early studies of fatigue in cancer popula-
tions were limited by the use of poorly validated 
assessment instruments and the lack of a coher-
ent deﬁ nition of cancer-related fatigue syndrome 
(CRFS).8 However, in 1998 Cella and colleagues9 
proposed the introduction of diagnostic criteria for 
CRFS, which have now been successfully applied 
in a number of clinical studies.10–14 These criteria 
are based on similar principles to those used to 
diagnose patients with chronic fatigue syndrome 
(CFS).15 Most recently, our own group rigorously 
applied the diagnostic criteria to BCS between 3 
months and 2 years after completion of treatment. 
We found the prevalence of CRFS to be 30%.16
CRFS is a clinical diagnosis and as such relies 
on the subjective reports of patients. Broadly 
speaking, patients’ complaints of fatigue relate to 
either decrements in motor performance (physi-
cal fatigue) or impaired cognitive abilities (men-
tal fatigue). Unfortunately, the same term can 
be used to describe both an objective physical or 
mental decrement in performance and a subjec-
tive mental state. Both types of fatigue are usu-
ally found to a greater or lesser extent in the same 
individual. However, there is no direct correspon-
dence between the two phenomena. It is quite 
possible to feel extremely subjectively fatigued 
but to perform relatively normally on objective 
tests of physical or mental functioning.
However, patients’ subjective complaints of 
physical fatigue relate to changes in the activities 
of daily living, mobility and the need for daytime 
naps. Unobtrusive objective monitoring is required 
to investigate these phenomena and studies have 
been performed using actigraphy (real-time activ-
ity monitoring). Overall, the data from several 
studies17 18 suggest that there is a strong correla-
tion between changes in subjective fatigue and 
actigraphy data measures. The most consistent 
correlations occur between fatigue measures and 
disruption of sleep quality. However, the limita-
tions of and variations in data collection mean 
these ﬁ ndings need further conﬁ rmation. In par-
ticular, these data have been recorded in patients 
on treatment and linked to sleep disturbances and 
have not adequately assessed the level of daytime 
fatigue. The exception to this was a study by our 
group16 in which, contrary to expectation, we 
found no signiﬁ cant differences in activity levels 
in a population of fatigued BCS compared to non-
fatigued controls.
Several researchers have investigated cognitive 
changes in cancer survivors. Recent systematic 
reviews19 and a meta-analysis3 concluded that 
there is some evidence of objective declines in 
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cognitive function (particularly verbal memory and execu-
tive function) following chemotherapy, but only one previous 
study has attempted to relate these objective ﬁ ndings to sub-
jective complaints of fatigue.20 However, the authors did not 
use the diagnostic criteria9 and only employed a limited range 
of cognitive testing.
The primary aim of this study was to examine differences 
in objective measures of cognition (speciﬁ cally focusing on 
previously identiﬁ ed cognitive domains that were affected) 
and in physical activity in women who did or did not meet the 
criteria for CRFS.
MATERIALS AND METHODS
BCS were recruited from January 2009 to May 2011 from a sin-
gle centre nurse-led follow-up clinic at St George’s Healthcare 
NHS Trust. Approval was obtained from Wandsworth ethics 
committee prior to data collection (ref 08/H0803/182).
All patients who were clinically and radiologically disease-
free between 3 months and 2 years after the end of their pri-
mary treatment (of any modality) were invited to participate. 
Concurrent hormone use was allowed.
Those patients with signiﬁ cant cognitive impairment, a 
psychiatric history or medical co-morbidities on notes review 
or initial discussion with the researcher (OM) were excluded 
from entering the study (12 women in total). This was a prag-
matic decision as these women were not eligible for the com-
plete study.
Eligible women were identiﬁ ed from the clinic list 14 days 
before their appointment and received an introductory letter 
and an information sheet by post. Women who declined to 
participate in the study were asked if they would be willing to 
complete a short fatigue questionnaire.
Assessment 1
Women who consented to participate were invited to an initial 
consultation in a designated research facility and completed 
the following interviews and actigraphy.
Diagnostic Interview for Cancer-Related Fatigue
This interview determines whether the participant meets the 
four criteria for a diagnosis of CRFS9: criterion A—the pres-
ence of 2 weeks of signiﬁ cant fatigue in the preceding month 
and the presence of at least ﬁ ve out of nine other fatigue-
related symptoms; criterion B—the fatigue has a signiﬁ cant 
effect on work or self-care; criterion C—the fatigue symptoms 
are a consequence of cancer or cancer therapy; and criterion 
D—the symptoms are not primarily a consequence of a co-
morbid psychiatric disorder. The ﬁ nal criterion can be assessed 
clinically, but the most robust method is to use a contempo-
raneous psychiatric interview. Participants with a signiﬁ cant 
psychiatric history which was felt to be contributing to fatigue 
were excluded.
Structured Clinical Interview for the DSM–IV (SCID)
The Structured Clinical Interview for the DSM-IV (SCID) pro-
vides a method for obtaining Diagnostic and Statistical Manual 
(DSM)-IV diagnoses. The procedure has been successfully used 
in previous studies examining CRFS11 12 and by our group.16 All 
interviews were conducted by the same person (OM). The SCID 
can be administered by a non-psychiatrist. OM was trained in 
administration and supervised by a consultant liaison psychia-
trist. The average administration time was 30 min.
Other questionnaires
All women were also asked to complete the following 
questionnaires:
(1) Functional Assessment of Cancer Therapy (FACT-F). This 
is a 13-item questionnaire to measure fatigue21 in cancer 
and has been widely used in cancer treatment trials.22
(2) The Chalder Fatigue Scale (FS).23 This is an 11-item ques-
tionnaire to measure fatigue. It was originally developed 
in non-cancer patients but has been extensively used in a 
number of studies in cancer.24
(3) All participants were asked to give a score of average fatigue 
over the last week on a 0–10 visual analogue scale (VAS-F), 
where 0 is no fatigue and 10 is fatigue as bad as you can 
imagine (after National Comprehensive Cancer Network 
(NCCN) guidance).25
(4) Hospital Anxiety and Depression Scale (HADS). This is a 
14-item scale with seven items on anxiety and seven items 
on depression.26 It is used extensively in clinical trials and 
has been employed by our group previously in fatigue 
assessment studies.27
(5) European Organisation of Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-30). 
This is a 30-item instrument with ﬁ ve functional scales, 
three symptom scales and a global quality of life score.28
(6) EORTC Breast Module (BR23). This is a 23-item scale which 
is validated for use in breast cancer patients.29 It includes 
items on breast and arm symptoms and systemic treatment 
effects.
(7) The 7-item Insomnia Severity Index (ISI).30 This scale has 
previously been validated in a breast cancer population.31 
The seven items in this scale were combined with two 
additional sleep related questions to determine if insomnia 
diagnostic criteria were met:
▶ During the past month how many nights per week have 
you taken more than 30 min to fall asleep?
▶ During the past month how many nights per week were 
you awake for more than 30 min?
A diagnosis of insomnia syndrome was made if one of the 
above two features was present on more than three nights per 
week on average, there was signiﬁ cant distress as scored on 
the ISI and/or fatigue or daytime somnolence was present. It 
took 20 min on average to administer these questionnaires 
and conduct the CRFS interview. An initial appointment time 
of an hour was made and potential participants were made 
aware of this time requirement.
Actigraphy
After completion of the questionnaires and interview, par-
ticipants were asked to wear an Actiwatch AW4 (CamNtech, 
Cambridge, UK) for a period of 7 days and nights. The associ-
ated software and sleep algorithm32 allows for the determi-
nation of selected measures of activity, sleep and circadian 
rhythm (over a 7-day average). A predetermined 12 h time-
frame is used to deﬁ ne daytime (light) activity: 06:00 to 18:00 
h. The night-time activity period (dark) is deﬁ ned as 18:00 to 
06:00 h. The participants used an event marker on the watch 
to record their own individualised sleep patterns. This was 
recorded as the time entering and exiting bed overnight and 
did not include naps.
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Assessment 2
Participants underwent objective cognitive testing using a 
predetermined computerised battery approximately 1 week 
later (CANTABeclipse, Cambridge Cognition, Cambridge, 
UK). The procedure uses a touch screen computer (Slimbook 
P210; PaceBlade, Amersfoort, The Netherlands) and press pad. 
It consists of seven different tests designed to assess the cogni-
tive domains thought to be affected by previous breast cancer 
treatment.19 This computerised battery has been previously 
used in a longitudinal study of cognitive changes after breast 
cancer treatment.33 The procedure takes 45 min to complete 
and was administered by one of the authors (OM).
The tests and cognitive domains studied are listed below:
Paired Associates Learning (PAL; visuospatial ability  ▶
and visual memory)
Rapid Visual Information Processing (RVP; sustained  ▶
attention and reaction time – motor skills)
Match to Sample Visual Search (MTS; visuospatial  ▶
ability and motor skills)
Verbal Recognition Memory (VRM; verbal memory) ▶
Delayed Matching to Sample (DMS; attention) ▶
Affective Go No-go (AGN; decision and response and  ▶
information processing)
Intra-Extra Dimensional Set Shift (IED, executive  ▶
function/information processing).
Statistical considerations
The power calculation was based on an estimated sample size 
of 96 women. With 48 cases and 48 controls, the study would 
have had 80% power to detect a 0.57 (medium) between-
group effect size on questionnaire and objective monitoring 
data at a 5% signiﬁ cance level. Since this was an exploratory 
and hypothesis generating study, no correction was made for 
multiple analyses. The between-group analysis was conducted 
using t tests with comparisons between mean scores.
RESULTS
Due to time and resource constraints, recruitment of fatigued 
patients terminated slightly early with 45 of an expected 48 
patients recruited. However, the number of control subjects 
was larger than required. A total of 114 women completed the 
study (69 controls and 45 cases of CRFS). Non-participants 
(NP=102) were asked to complete the Chalder fatigue question-
naire and ethics approval was obtained to collect anonymised 
demographic and treatment data from these women. The 
main reasons for non-participation were cited as work (28%) 
or the need for extra visits (32%), while 12% mentioned other 
medical problems and the remainder either had ‘had enough’ 
or did not want to think about their cancer (28%). The NP had 
a signiﬁ cantly lower fatigue score (10.7 vs 13.1; p=0.04) and 
were older (62 years vs 57 years; p=0.005) than the partici-
pants. There were no differences on treatment variables, stage 
at diagnosis or time since diagnosis.
Cases versus controls
The overall prevalence of CRFS was 39% (45/114). A 
between-group comparison for all data is shown in tables 1–5 
(table 1: treatment variables; table 2: questionnaire data; table 3: 
routine laboratory parameters; table 4: actigraphy data; and 
table 5: cognitive testing data).
There were no signiﬁ cant differences between groups in 
mean age (CRFS 56.0 years vs controls 58.6 years; p=0.17), time 
since treatment (CRFS 12.4 months vs controls 13.0 months; 
p=0.67) or body mass index (CRFS 27.1 kg/m2 vs controls 26.0 
kg/m2; p=0.29).
There were no signiﬁ cant differences in treatment variables 
between groups (table 1).
There was a signiﬁ cantly higher prevalence of oestrogen 
receptor negative tumours in the control group. There was 
no difference in the percentage of non-white participants 
between groups.
There were signiﬁ cant differences in the levels of fatigue, 
mood disturbance and quality of life. There were also a num-
ber of differences in symptom subscales on both the EORTC 
QLQ-30 and BR23 (table 2).
The prevalence of insomnia syndrome was signiﬁ cantly 
higher in the CRFS group (44% vs 16%; p=0.001).
The routine laboratory variables (table 3), measured to 
exclude any gross metabolic disturbance, did not show any 
signiﬁ cant differences between groups.
The actigraphy data (table 4) which provided a measure of 
sleep, activity and circadian rhythm, demonstrated some dif-
ferences. There was a minor difference in sleep with the control 
group actually having signiﬁ cantly shorter sleep bouts. However, 
there were no differences in the major sleep parameters (overall 
time or quality). There were signiﬁ cant differences in average 
daytime activity and duration of daytime (light) activity.
The cognitive data (table 5) demonstrated subtle but impor-
tant differences between the groups. Signiﬁ cant differences 
Table 1 Treatment and pathological variables
CRFS cases Controls
Treatment variable Frequency Percentage Frequency Percentage p Value
Conserving surgery 31 69 40 58 0.24
Non-conserving surgery 14 31 29 42
Chemotherapy 19 42 35 51 0.37
No chemotherapy 26 58 34 49
Radiotherapy 39 87 51 74 0.10
No radiotherapy 6 13 18 26
Hormone therapy 6 13 11 16 0.79
No hormone therapy 39 87 58 84
Lymph node positive 17 38 17 25 0.13
Lymph node negative 28 62 52 75
Oestrogen receptor positive 42 93 54 78 0.03
Oestrogen receptor negative 3 7 15 22
HER2 receptor positive 6 13 8 12 0.78
HER2 Receptor negative 39 87 61 88  
CRFS, cancer-related fatigue syndrome.
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reference range Mean SD Mean SD p Value
Haemoglobin (g/dl)  12–16 12.9 0.78 12.9 0.91 0.94
White cell count (×109/l)   4–11 5.89 1.51 6.12 2.1 0.26
Neutrophil (×109/l)   1.7–8.0 3.54 1.08 4.41 4.7 0.17
Lymphocyte (×109/l)   1.0–4.0 1.84 0.71 1.80 0.68 0.79
Monocyte (×109/l)   0.24–1.1 0.36 0.16 0.37 0.12 0.60
Platelet (×109/l) 150–450 274 55.5 269 53.7 0.63
Sodium (mmol/l) 135–145 139.27 2.07 139.52 2.22 0.55
Potassium (mmol/l)   3.5–4.7 4.18 0.34 4.20 0.23 0.744
Urea (mmol/l)   2.5–8.0 5.48 1.19 5.74 1.53 0.32
Creatinine (µm/l)  60–110 64.10 8.29 66.59 8.20 0.13
Uncorrected calcium (mmol/l)   2.18–2.47 2.36 0.099 2.37 0.099 0.56
Adjusted calcium (mmol/l) NA 2.38 0.085 2.40 0.085 0.31
Phosphate (mmol/l)   0.75–1.50 1.12 0.15 1.08 0.20 0.24
Alkaline phosphatase (IU/l)  30–100 74.07 21.86 67.58 19.56 0.12
Alanine transaminase (IU/l)   0–40 25.16 11.16 27.72 14.17 0.32
Bilirubin (µmol/l)   0–17 6.81 3.15 7.35 2.98 0.37
Albumin (g/l)  35–48 38.67 2.90 38.56 2.06 0.83
GGT (IU/l)   0–30 29.33 23.54 30.49 24.92 0.81
TSH (mU/l)   0.4–4.0 2.63 3.31 3.25 5.05 0.50
Free T4 (pmol/l)  12–24 13.36 4.17 13.04 3.14 0.67
Magnesium (mmol/l)   0.74–1.03 0.86 0.68 0.86 0.08 0.74
CRFS, cancer-related fatigue syndrome; GGT, gamma-glutamyl transpeptidase; TSH, thyroid stimulating hormone.
were found on the RVP and VRM tests. The AGN test, a sen-
sitive measure of executive function, demonstrated a higher 
number of commissions (ie, incorrect responses) in the CRFS 
group. The CRFS group performed worse than the controls in 
all statistically signiﬁ cantly different tests.
DISCUSSION
This study is the ﬁ rst to objectively characterise cognitive dif-
ferences between a rigorously deﬁ ned group of cases of CRFS 
and a group of non-fatigued BCS. We found no differences in 
sleep actigraphy despite a much higher prevalence of insomnia 
Table 2 Questionnaire data
CRFS cases Controls
Variable Mean SD Mean SD p Value
FS total 18.87 5.35 9.22 6.35 <0.001
FACT-F total 26.84 8.07 14.54 6.83 <0.001
ISI total 13.96 5.99 9.01 5.98 <0.001
HADS total 14.82 6.47 7.26 5.03 <0.001
VAS-F scale 6.44 1.53 4.73 2.29 <0.001
EORTC QLQ-30 subscales
 Physical functioning 69.19 19.45 85.80 14.00 <0.001
 Global health status 81.09 16.80 56.07 22.79 <0.001
 Emotional functioning 63.70 20.73 80.80 17.98 <0.001
 Cognitive functioning 56.67 23.41 79.47 19.63 <0.001
 Social functioning 59.26 27.65 84.81 19.69 <0.001
 Fatigue 55.80 21.52 25.44 17.68 <0.001
 Nausea/vomiting 7.04 13.98 2.42 6.57 0.04
 Pain 37.04 33.88 16.91 21.86 0.01
 Dyspnoea 22.96 27.36 11.59 19.66 0.02
 Insomnia 48.15 32.22 37.68 32.29 0.09
 Appetite loss 11.85 23.74 7.25 14.98 0.25
 Constipation 12.59 23.88 6.28 14.32 0.15
 Diarrhoea 2.96 9.59 3.86 13.45 0.68
 Financial diffi culties 31.85 34.78 9.18 20.52 <0.001
EORTC BR23 subscales
 Br east systemic therapy side 
effects
30.37 16.22 16.25 11.53 <0.001
 Breast symptoms 38.89 18.63 20.05 16.69 <0.001
 Arm symptoms 32.59 29.24 12.91 16.25 <0.001
The VAS-F is a visual analogue fatigue scale from 0 to 10. Values indicate average fatigue over the last 7 days.
The EORTC QLQ-30 (European Organisation for Research and Treatment of Cancer 30-item Quality of Life 
Questionnaire) has defi ned subscales of functioning and symptom scores. Higher scores on symptom subscales 
indicate greater symptom severity, and higher scores on functional subscales indicate better functioning.
The EORTC BR23 is a breast specifi c module with functioning and symptom scales.
CRFS, cancer-related fatigue syndrome; FACT-F, Functional Assessment of Cancer Therapy – fatigue subscale; 
FS, Chalder Fatigue Scale; HADS, Hospital Anxiety and Depression Scale; ISI, Insomnia Severity Index.
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Table 4 Actigraphy data
CRFS cases Controls
Variable Mean SD Mean SD p Value
Sleep
 Actual sleep time (h) 06:04 00:44:41 06:07 00:45:56 0.74
 Actual sleep (%) 84.40 6.41 82.49 10.28 0.27
 Actual wake time (h) 01:07 00:28:29 01:11 00:30:31 0.48
 Actual wake (%) 17.51 10.27 15.60 6.41 0.28
 Sleep effi ciency (%) 80.22 7.73 78.44 13.28 0.43
 Sleep latency (min) 00:17:32 00:20:27 00:17:19 00:27:36 0.97
 Av erage number of calculated sleep 
bouts
23.73 6.60 24.04 7.02 0.82
 Av erage number of calculated wake 
bouts
23.77 6.68 24.10 7.02 0.81
 Me an sleep bout time (min) 00:33:03 00:44:41 00:19:20 00:13:41 0.02
Activity
 Mean wake bout time (min) 00:02:43 00:00:42 00:03:25 00:00:28 0.19
 Av erage value of epoch intensity 
(24 h period)
208.48 87.22 245.82 96.32 0.04
 Di fference in maximum and 
minimum activity
198.85 69.70 218.55 88.97 0.45
 Peak intensity of epoch 11.91 5.02 11.99 4.68 0.22
 Average of daytime (light) activity 299.25 131.18 342.92 119.92 0.03
 Time of night time (dark) activity 117.70 55.24 148.72 90.60 0.14
 Ratio of light to dark activity 2.99 1.54 2.99 1.54 0.82
Circadian rhythm
 Interdaily stability 0.53 0.12 0.57 0.15 0.16
 Interdaily variability 0.86 0.21 0.83 0.21 0.14
 Least 5 (L5) active hours 1475 1010 2348 1634 0.50
 Most 10 (M10) active hours 22481 7774 24865 8722 0.50
 Relative amplitude 0.88 0.07 0.86 0.14 0.22
Sleep effi ciency (%) is time asleep (as per algorithm) divided by total time in bed.
Sleep latency is time in bed before algorithm records the subject being asleep.
Average value of epoch intensity (24 h period): the recording is converted to and analysed as a cosine wave around 
a zero point.
Difference in maximum and minimum in activity corresponds to the difference between the peak and trough of the 
cosine wave.
Interdaily stability is a measure of consistency in daily activity over 7 days.
Interdaily variability is a measure of fragmentation of periods of rest and activity; normal value are <1 and 
calculated over 7 days.
L5 indicates the 5 h of calculated lowest activity over the 7-day average.
M10 indicates the 10 h of calculated greatest activity over the 7-day average.
Relative amplitude is a measure of the difference between L5 and M10 and thus an indication of overall level of 
activity over the 7-day period.
CRFS, cancer-related fatigue syndrome.
syndrome in the CRFS group. However, mean daytime activ-
ity was lower in the CRFS group. These ﬁ ndings raise impor-
tant questions about the nature of CRFS and its relationship to 
objective deﬁ cits in activity and cognition.
The strengths of this study are the tight categorisation of 
post-treatment fatigue in BCS and the extensive cognitive and 
activity testing. However, the sample size is small and it is 
only a single centre study. The multiple analyses may have 
led to type I errors. This was a hypothesis generating study 
and was underpowered to detect all the identiﬁ ed differences 
between the groups, so the discussion and conclusions should 
be interpreted in that context. However, we feel these are 
interesting data and are further validated when placed in the 
context of previous ﬁ ndings.
The domains in which cognitive dysfunction occurs are 
the same as identiﬁ ed in previous reviews of breast cancer 
patients.19 The areas of executive function, processing speed 
and verbal memory are important for day-to-day tasks and 
may explain why these are associated with the subjective sen-
sation of mental fatigue. Similar ﬁ ndings were found in a com-
parative study between subjects with CFS and cancer fatigue34 
but not in a study comparing fatigued and non-fatigued 
BCS.20 However, in the latter study it should be noted that the 
‘fatigued’ BCS group were deﬁ ned using a cut-off on a continu-
ous fatigue scale (rather than using a case-based deﬁ nition) and 
the cognitive testing only included measures of concentration 
and reaction time (rather than the more comprehensive bat-
tery of tests employed in the current study). The authors failed 
to ﬁ nd differences between the fatigued and the non-fatigued 
group on objective cognitive testing. The objective evidence of 
cognitive impairment that we identiﬁ ed in this study appears 
to be consistent with the questionnaire data. The Chalder 
Fatigue Scale and the QLQ-30 both assess perceived cognitive 
impairment, and the scores on both of these questionnaires 
were signiﬁ cantly worse in the CRFS group.
One limitation of the cognitive assessments undertaken 
in this study was that they were only recorded at the end of 
treatment and were not measured prospectively from base-
line. However, we were not speciﬁ cally examining cognitive 
change per se following treatment but comparing CRFS and 
matched controls. The purpose was to identify potential cog-
nitive deﬁ cits in the CRFS group. The exclusion of psychiatric 
co-morbidities reinforces the hypothesis that CRFS is associ-
ated with a deﬁ ned set of cognitive deﬁ cits that are unrelated 
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to mood disturbance. The underlying mechanism of cognitive 
dysfunction is unclear and may be related to an increase in 
circulating inﬂ ammatory cytokines35 but seems unlikely to be 
related to a gross hypothalamic pituitary axis disturbance.36 
Functional imaging studies in this population would help to 
further elucidate the mechanism. The association between 
subjective fatigue and objective cognitive deﬁ cits is also inter-
esting in relation to the ﬁ nding that psychostimulants can 
reduce cancer fatigue during treatment.37 However, they are 
unlikely to be suitable for longer term use in BCS38 because of 
concerns related to adverse effects and the risk of addiction.
The higher prevalence of insomnia syndrome in the CRFS 
group was linked to higher scores on the ISI. However, this 
subjective perception of difﬁ culty with sleeping did not cor-
relate with objective actigraphy measures of sleep. While 44% 
of CRFS meet the criteria for insomnia syndrome, they are 
clearly two separate entities and CRFS cannot be explained 
by sleep disturbances alone. This ﬁ nding is supported by data 
from an intervention trial for insomnia that improved sleep 
but not fatigue.39
We found signiﬁ cant differences between groups with 
respect to objective activity data. This is in keeping with 
a recent study40 in breast cancer but in conﬂ ict with our 
earlier ﬁ ndings.16 The reason for the disparity is unclear 
but may be due to the different actigraph used and asso-
ciated analysis algorithm. The differences were seen in 
the average epoch score (a measure of movement inten-
sity) and in the level of daytime activity. These data con-
ﬁ rm that patients who fulﬁ l the criteria for CRFS, as well 
as being subjectively more fatigued, also have evidence of 
decreased physical activity. The decreased activity may 
be a direct consequence of feeling subjectively fatigued, 
or the decreased activity may arise ﬁ rst (due to a variety 
of causes) and may be a causative factor in exacerbating or 
perpetuating the subjective fatigue that these patients expe-
rience.41 One way to disentangle these phenomena would 
be to undertake a longitudinal study to assess both subjec-
tive and objective manifestations of fatigue and to trace the 
temporal relationships between them.40 The authors of the 
study40 did not use diagnostic criteria to measure fatigue. 
The theory that, whatever the cause of the initial fatigue, 
it is perpetuated by physical deconditioning and decreased 
activity probably explains why exercise is reported to be an 
effective treatment for cancer related fatigue.42 It is likely, 
however, that the effects of exercise are relatively non-spe-
ciﬁ c (exercise reduces fatigue even in healthy individuals) 
and this explains the relatively small effect size for exercise 
interventions in cancer populations.
In a previous study in BCS we found the prevalence of CRFS 
to be 30%16 and this general ﬁ gure was supported by the results 
of a systematic review.7 The prevalence of 39% for CRFS that 
we found in this study although slightly higher than previous 
Table 5 Cognitive testing data
CRFS cases Controls
Variable Mean SD Mean SD p Value
DMS percentage correct (all delays) 81.78 11.63 84.83 11.43 0.17
DMS mean correct latency (ms) 3528 1151 3707 1416 0.48
IED stages completed 7.40 2.40 7.33 2.40 0.89
IED total errors (adjusted) 50.37 51.71 52.65 53.43 0.83
MTS mean correct reaction time 3515 1143 3156 1137 0.10
MTS per cent correct 94.32 6.10 93.38 5.78 0.41
PAL stages completed 3.40 0.78 3.50 0.86 0.76
PAL total errors (adjusted) 95.60 29.67 92.90 32.05 0.65
PAL total trials (adjusted) 20.47 6.78 20.09 7.29 0.78
RVP A´  (scores between 0 and 1) 0.87 0.06 0.89 0.07 0.15
RVP total correct rejections 236.69 25.83 245.53 14.95 0.02
RVP mean latency (ms) 533 127 468 126 0.009
VRM free recall – total correct 7.00 1.77 7.75 1.75 0.03
VRM recognition – total correct 22.78 1.38 23.06 1.42 0.3
AGN mean correct latency (ms) 532 71 517 61 0.24
AGN total omissions 5.17 1.99 4.57 1.78 0.64
AGN total commissions 7.76 1.75 6.57 1.72 0.03
AGN: Affective Go No-go (information processing and reaction time). There are three outcomes: mean correct 
latency (time taken for a correct response), total omissions which are incorrect responses to a target word (ie, 
the subject not pressing the button when they should have) and total commissions which are the total number of 
incorrect responses to the distracter words (ie, pressing the button inappropriately).
DMS: Delayed Matching to Sample (memory and reaction time). There are two outcomes: overall correct responses 
(percentage) and latency of response (time taken to make correct response).
IED: Intra-Extra Dimensional Set Shift (rule acquisition and reversal). There are two outcomes: stages complete 
is the number successfully completed and total errors (adjusted for stages) is a measure of the effi ciency of 
completing the test.
MTS: Match To Sample (matching test with speed/accuracy trade off). There are two outcomes: overall correct 
responses (percentage) and latency of response (time taken to make correct response).
PAL: Paired Associates Learning (visual memory and new learning). There are two outcomes: total errors (adjusted 
from stages completed) and total trials (number of attempts needed to complete task adjusted for early abortion).
RVP: Rapid Visual Information Processing (sensitive measure of general performance). There are three outcomes: 
A´  is a probability score of how good a participant is at detecting sequences, correct rejection is the number of 
times a false sequence is ignored between correct ones and the mean latency is the time of response between the 
end of a sequence and the participant pressing the button.
VRM: Verbal Recognition Memory (verbal information under free recall and forced choice recognitions). There are 
two outcomes: free recall number of correct words and a forced choice correct total (yes/no as to whether word 
was in the original list).
CRFS, cancer-related fatigue syndrome.
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estimates is broadly in keeping with these ﬁ gures and may be 
explained by the ﬁ nding that the non-participant group were 
signiﬁ cantly less fatigued16 than the study sample. A preva-
lence of 30–39% represents a sizeable percentage of women 
who have successfully completed treatment for breast cancer 
and potentially translates into a large absolute number of BCS. 
This emphasises that it is important to recognise and treat 
fatigue.
The widespread differences in questionnaire data and levels 
of other symptoms are in keeping with previous studies.12 We 
found that the CRFS group had a higher level of mood distur-
bance despite the exclusion of patients with speciﬁ c psychiatric 
diagnoses. It is possible that sub-threshold mood disturbance 
contributes to CRFS. However fatigue and depression should 
be regarded as separate entities.43
There are some important negative ﬁ ndings in this study. 
There were no signiﬁ cant differences in any of the routine lab-
oratory tests. While fatigue may be linked to anaemia during 
chemotherapy,44 this does not appear to be the case in BCS. 
There is also no link to thyroid disturbances. We had postu-
lated that serum magnesium levels may be contributory but 
this was not found to be the case.
There were also no differences in treatment or demographic 
variables between groups. This is consistent with a critical 
appraisal45 in which the authors found very limited associa-
tions between fatigue and these variables.
The clinical signiﬁ cance of these ﬁ ndings reinforces the 
importance of identifying women who have or are at risk of 
developing CRFS. This should be incorporated into routine 
practice and might include counselling on potential cogni-
tive and sleep changes. These problems might be diminished 
with simple information giving at the start of treatment,46 
which would in keeping with the Department of Health 
survivorship strategy.47 However, we are not able to rec-
ommend any particular treatment strategy at present in 
this group.7 In conclusion, we have found that a signiﬁ cant 
minority of women successfully treated for breast cancer 
meet the criteria for CRFS. This group is characterised by 
subjective poly-symptomology. There are important differ-
ences between the groups with objectively lower cognitive 
function and daytime activity in the CRFS group that need 
further conﬁ rmation with a larger sample size. Future work 
should examine this relationship longitudinally, possibly 
within a quality of life arm of a treatment trial. Correlation 
with levels of cytokines and/or functional imaging would 
be helpful to further characterise this group. The overall 
aim should be to design more targeted treatments to man-
age this problematic syndrome.
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